Melphalan or Cyclophosphamide with Lenalidomide/Prednisone versus Lenalidomide/Dexamethasone for Newly Diagnosed MM


Melphalan or Cyclophosphamide with Lenalidomide/Prednisone versus Lenalidomide/Dexamethasone for Newly Diagnosed MM
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Sagar Lonial, MD (1/22/14)
Palumbo A et al. A randomized Phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs lenalidomide plus dexamethasone (Rd) in elderly newly diagnosed multiple myeloma patients. Proc ASH 2013;Abstract 536.

Dr Lonial is Professor, Vice Chair of Clinical Affairs and Director of Translational Research for the B-Cell Malignancy Program in the Department of Hematology and Medical Oncology at the Emory University School of Medicine Winship Cancer Institute in Atlanta, Georgia.